Kyntra Bio (KYNB) EBT Margin (2014 - 2026)
Kyntra Bio (KYNB) posted EBT Margin of 404.82% for Q1 2026, up 64.62% sequentially from 1144.09% in Q4 2025, and up 20723.0% YoY from N/an in Q1 2025.
Kyntra Bio (KYNB) EBT Margin (2014 - 2026) Analysis & Trends
Kyntra Bio has reported EBT Margin for 13 years, with the latest figure at 404.82% in Q1 2026.
- Quarterly EBT Margin rose 20723.0% year-over-year to 404.82% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 761.7% (up 113125.0% YoY) and the FY2025 annual result came in at 905.19%, down 38742.0% from the prior year.
- EBT Margin advanced to 404.82% in Q1 2026 per KYNB's latest filing, from 1144.09% in the prior quarter.
- Over five years, EBT Margin peaked at 126.16% in Q4 2023 and troughed at 39259.35% in Q3 2024.
- A 5-year average of 3851.92% and a median of 647.06% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin sank 3909937 bps in 2024, then jumped 3803760 bps in 2025.
- Over 5 years, EBT Margin stood at 789.85% in 2022, then jumped by 116 bps to 126.16% in 2023, then plunged by 319 bps to 276.33% in 2024, then sank by 314 bps to 1144.09% in 2025, then soared by 65 bps to 404.82% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 404.82%, 1144.09%, and 1221.75% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Kyntra Bio | 29.83 Mn | 29.83 Mn | 1.47 Mn | 812.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 812.28% |
| Mar 31, 2026 | -404.82% |
| Dec 31, 2025 | -1,144.09% |
| Sep 30, 2025 | -1,221.75% |
| Jun 30, 2025 | -1,021.88% |
| Mar 31, 2025 | -612.05% |
| Dec 31, 2024 | -276.33% |
| Sep 30, 2024 | -39,259.35% |
| Jun 30, 2024 | -11,844.00% |
| Mar 31, 2024 | -2,229.05% |
| Dec 31, 2023 | 126.16% |
| Sep 30, 2023 | -159.98% |
| Jun 30, 2023 | -614.34% |
| Mar 31, 2023 | -4,554.53% |
| Dec 31, 2022 | -789.85% |
| Sep 30, 2022 | -584.32% |
| Jun 30, 2022 | -245.47% |
| Mar 31, 2022 | -647.06% |
| Dec 31, 2021 | -811.88% |
| Sep 30, 2021 | 31.78% |